SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines

被引:11
|
作者
Khodavirdipour, Amir [1 ,2 ]
Keramat, Fariba [3 ]
Hashemi, Seyed Hamid [3 ]
Alikhani, Mohammad Yousef [4 ]
机构
[1] Univ Tabriz, Fac Nat Sci, Dept Biol, Tabriz, Iran
[2] St Johns Hosp, Div Human Genet, Dept Anat, Bangalore, Karnataka, India
[3] Hamadan Univ Med Sci, Fac Med, Dept Infect Dis, Hamadan, Iran
[4] Hamadan Univ Med Sci, Dept Microbiol, Hamadan, Iran
来源
AIMS MOLECULAR SCIENCE | 2020年 / 7卷 / 03期
关键词
COVID-19; vaccine; drug discovery; hrsACE2; ivermectin; famotidine; PNEUMONIA;
D O I
10.3934/molsci.2020013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
All species of coronavirus may cause infections in birds which is known to us since the 60s, but recently, from Nov 2019, the disease emerged in humans from the seafood market in Wuhan city. The previous viral outbreaks like SARS-CoV and MERS-CoV have also shown a greater mortality rate when transmitted to humans than other animals. An emerging concern in the 2019 novel coronavirus (SARS-CoV-2) is in terms of developing vaccine or discovery of new drugs to overcome the current viral pandemic. In this rapid-review, we aim to update the available data on coronavirus with the latest findings and achievements. So far, great steps have been taken such as hrsACE2 by a Swedish team from Karolinska Institute. Monash University announced the efficacy of Ivermectin to overcome COVID-19. The CRISPR/Cas13d as a new innovative therapeutics based might overcome the challenge of COVID-19. those strains of virus which lacking E protein-encoding regions are the perfect choice for vaccine development.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 50 条
  • [1] The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection
    Xue, Vivian Weiwen
    Wong, Sze Chuen Cesar
    Li, Bo
    Cho, William Chi Shing
    EXPERT OPINION ON DRUG DISCOVERY, 2023, 18 (07) : 769 - 780
  • [2] Drug Discovery Strategies for SARS-CoV-2
    Shyr, Zeenat A.
    Gorshkov, Kirill
    Chen, Catherine Z.
    Zheng, Wei
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 375 (01): : 127 - 138
  • [3] SARS-CoV-2 replication and drug discovery
    Nazir, Farah
    Kombe, Arnaud John Kombe
    Khalid, Zunera
    Bibi, Shaheen
    Zhang, Hongliang
    Wu, Songquan
    Jin, Tengchuan
    MOLECULAR AND CELLULAR PROBES, 2024, 77
  • [4] Drug discovery and development targeting the life cycle of SARS-CoV-2
    Su, Haixia
    Xu, Yechun
    Jiang, Hualiang
    FUNDAMENTAL RESEARCH, 2021, 1 (02): : 151 - 165
  • [5] Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development
    Oves, Mohammad
    Ravindran, Mithunan
    Rauf, Mohd Ahmar
    Omaish Ansari, Mohammad
    Zahin, Maryam
    Iyer, Arun K.
    Ismail, Iqbal M. I.
    Khan, Meraj A.
    Palaniyar, Nades
    PATHOGENS, 2020, 9 (12): : 1 - 16
  • [6] A community effort in SARS-CoV-2 drug discovery
    Schimunek, Johannes
    Seidl, Philipp
    Elez, Katarina
    Hempel, Tim
    Le, Tuan
    Noe, Frank
    Olsson, Simon
    Raich, Lluis
    Winter, Robin
    Gokcan, Hatice
    Gusev, Filipp
    Gutkin, Evgeny M.
    Isayev, Olexandr
    Kurnikova, Maria G.
    Narangoda, Chamali H.
    Zubatyuk, Roman
    Bosko, Ivan P.
    Furs, Konstantin V.
    Karpenko, Anna D.
    Kornoushenko, Yury V.
    Shuldau, Mikita
    Yushkevich, Artsemi
    Benabderrahmane, Mohammed B.
    Bousquet-Melou, Patrick
    Bureau, Ronan
    Charton, Beatrice
    Cirou, Bertrand C.
    Gil, Gerard
    Allen, William J.
    Sirimulla, Suman
    Watowich, Stanley
    Antonopoulos, Nick A.
    Epitropakis, Nikolaos E.
    Krasoulis, Agamemnon K.
    Pitsikalis, Vassilis P.
    Theodorakis, Stavros T.
    Kozlovskii, Igor
    Maliutin, Anton
    Medvedev, Alexander
    Popov, Petr
    Zaretckii, Mark
    Eghbal-Zadeh, Hamid
    Halmich, Christina
    Hochreiter, Sepp
    Mayr, Andreas
    Ruch, Peter
    Widrich, Michael
    Berenger, Francois
    Kumar, Ashutosh
    Yamanishi, Yoshihiro
    MOLECULAR INFORMATICS, 2024, 43 (01)
  • [7] HIV and SARS-CoV-2 Pathogenesis and Vaccine Development
    Fleury, Herve
    VIRUSES-BASEL, 2022, 14 (12):
  • [8] Development of an inactivated vaccine candidate for SARS-CoV-2
    Gao, Qiang
    Bao, Linlin
    Mao, Haiyan
    Wang, Lin
    Xu, Kangwei
    Yang, Minnan
    Li, Yajing
    Zhu, Ling
    Wang, Nan
    Lv, Zhe
    Gao, Hong
    Ge, Xiaoqin
    Kan, Biao
    Hu, Yaling
    Liu, Jiangning
    Cai, Fang
    Jiang, Deyu
    Yin, Yanhui
    Qin, Chengfeng
    Li, Jing
    Gong, Xuejie
    Lou, Xiuyu
    Shi, Wen
    Wu, Dongdong
    Zhang, Hengming
    Zhu, Lang
    Deng, Wei
    Li, Yurong
    Lu, Jinxing
    Li, Changgui
    Wang, Xiangxi
    Yin, Weidong
    Zhang, Yanjun
    Qin, Chuan
    SCIENCE, 2020, 369 (6499) : 77 - +
  • [9] SARS-CoV-2 vaccine candidates in rapid development
    Li, Lifeng
    Guo, Pengbo
    Zhang, Xiaoman
    Yu, Zhidan
    Zhang, Wancun
    Sun, Huiqing
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 644 - 653
  • [10] Development of SARS-CoV-2 Vaccine: Challenges and Prospects
    Mahboob, Tooba
    Ismail, Amni Adilah
    Shah, Muhammad Raza
    Rahmatullah, Mohammed
    Paul, Alok K.
    Pereira, Maria de Lourdes
    Wiart, Christophe
    Wilairatana, Polrat
    Rajagopal, Mogana
    Dolma, Karma G.
    Nissapatorn, Veeranoot
    DISEASES, 2023, 11 (02)